News for Healthier Living

AACR: Olaparib and Pembrolizumab Combination Shows Early Promise in Molecularly Selected, Tumor-Agnostic Trial

* Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations * Combination demonstrated complete responses and partial responses in different cancer types, including those beyond the currently approved indications for these therapies

April 27, 2025


April 29 2025

April 28 2025

April 27 2025

April 26 2025

April 25 2025

April 24 2025

April 23 2025

April 22 2025

April 21 2025

April 19 2025

April 18 2025

April 17 2025

April 16 2025

April 15 2025